# Safety and Efficacy of Inhaled Treprostinil in Patients With PAH

> **NCT01557647** · PHASE3 · WITHDRAWN · sponsor: **United Therapeutics**

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Inhaled treprostinil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01557647
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-06
- **Primary completion:** 2015-12
- **Final completion:** 2016-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01557647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01557647, "Safety and Efficacy of Inhaled Treprostinil in Patients With PAH". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01557647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*